The clinic notes tirzepatide shows promise in MASH liver disease studies but stresses it isn't FDA-approved for that use yet.
Recap by typeshit. Post by @brightonhealthcare on Instagram.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
This is the first time weight management has topped diabetes as the main reason. Users report eating fewer sweets, and 45% say they drink less alcohol.
GLP-1 researcher Daniel Drucker links to findings on Lilly's experimental retatrutide and sleep apnea. Details are at the link.
Loading…